Home > Healthcare > Medical Devices > Medical Supplies > Syringes and Needles Market
Syringes and Needles Market size will register significant growth between 2024 and 2032 due to government organizations consistently issuing recommendations and warnings regarding the risks associated with these medical devices.
For instance, in May 2021, the U.S. Food and Drug Administration urged healthcare providers to discontinue the use of specific syringes and needles produced by Chinese medical device manufacturer Guangdong Haiou Medical Apparatus Co (HAIOU). According to at least one pharmacist, these syringes were intended for use with the Pfizer Inc/BioNTech SE vaccine. The agency is confident that halting the use of these syringes will not result in any vaccination delays.
Concerns about needlestick injuries, cross-contamination, and improper disposal drive the need for safer and more advanced syringes and needles. Governments worldwide advocate for the adoption of safety-engineered devices to mitigate these risks and protect healthcare workers and patients. Consequently, there is a sustained demand for innovative syringe and needle technologies that prioritize safety and efficiency.
Governments passing crucial bills to ensure syringe and needle safety for the public are driving demand in the syringes and needles market. With legislative initiatives aimed at enhancing safety standards and minimizing risks associated with these medical devices, there's an increased focus on adopting advanced technologies and safety features. These measures are crucial for preventing needlestick injuries, reducing cross-contamination and safeguarding public health. Consequently, there's a growing demand for innovative syringes and needles that adhere to stringent safety regulations, promoting trust and confidence among healthcare providers and patients alike. For instance, in January 2024, advancing to the second round of voting with a 37-2 margin, LB307, introduced by Sen. Megan Hunt of Omaha, aimed to authorize pharmacies and public health services to supply safe syringes and needles to drug users, mitigating the spread of infectious diseases like HIV. Garnering bipartisan support, senators recognized its potential to enhance public safety in Nebraska.
The industry faces several restraints. Stringent regulatory requirements for product approval and compliance pose challenges for manufacturers. Cost constraints in healthcare settings may limit the adoption of advanced syringe and needle technologies. In addition, concerns about needlestick injuries and cross-contamination drive demand for safety-engineered devices, increasing production costs. Resistance to change from traditional practices and reluctance to invest in new technologies may also impede industry gains. Overcoming these restraints requires innovation, education, and regulatory alignment to ensure safer and more efficient healthcare delivery.
The industry is influenced by rising opposition to stringent safety rules for manufacturers. Some stakeholders argue that overly stringent regulations may stifle innovation and increase production costs, ultimately limiting industry progression. This opposition to stringent safety rules may lead to debates within the industry and among policymakers. However, balancing safety standards with industry innovation remains crucial to ensure the delivery of safe and effective healthcare products while addressing concerns about cost and regulatory burdens.
For instance, in December 2021, India's leading syringe and needle manufacturer, Hindustan Syringes and Medical Devices (HMD) appealed to Prime Minister Narendra Modi to rescind an order suspending production. This directive, issued by a state pollution control board as part of a broader factory shutdown to mitigate severe pollution in the area, forced HMD to close its factories near New Delhi. The shutdown raised concerns about potential shortages of syringes and needles in India, particularly amidst the country's ongoing COVID-19 vaccination campaign.
Disposable syringes and needles will account for a considerable share of the global market. The growth is attributed to high injection risks, the use of injectables as a mode of drug delivery, and the rising aging population. Moreover, affordability and safety attributes have made disposable syringes highly sought-after among the end-users. Disposable syringes and needles offer significant advantages in infection control and prevent needlestick injuries. As healthcare providers prioritize patient safety and infection prevention, the demand for disposable syringes and needles continues to rise.
Syringes and needles industry share from hospitals will expand through 2032 owing to investments in healthcare infrastructure. The growing prevalence of chronic diseases in Asia Pacific, North America and Middle East and Africa will further expedite the demand for syringes. Industry participants expect prefilled syringes to boost the sustainability portfolio by reducing multi-dose vials and product waste. Hospitals prioritize patient care and safety, relying on high-quality syringes and needles to deliver precise and safe treatments. With a constant influx of patients and medical procedures, hospitals represent a significant customer base, driving sustained demand for syringes and needles in the healthcare sector.
North America syringes and needles market outlook will be strong following the rise in cardiovascular diseases (CVD). According to the U.S. CDC, one person dies every 36 seconds from CVD in the U.S. Considering the significance of needles and syringes for CVD therapies and treatment, North America is likely to be a lucrative region during the forecast timeline. The region's commitment to modern healthcare practices and stringent regulatory standards further amplifies the demand for reliable and innovative syringes and needles, shaping the industry dynamics in North America.
Major companies operating in the syringes and needles industry competitive landscape include:
In January 2023, Schreiner MediPharm, renowned for pharmaceutical labels, introduced a new security feature enhancing its Needle-Trap label. This innovation included a seal indicating if a prefilled syringe has been previously opened, ensuring its integrity until final use. Combining needle and product protection, this solution debuted at Pharmapack in Paris. Pharmaceutical manufacturers prioritized supply chain security and packaging integrity, particularly with regulations like the EU Falsified Medicines Directive addressing secondary packaging.